Name: SB203580 (Adezmapimod)
Brand: Selleck Chemicals
SKU: S1076
Availability: InStock
Rating: 5 (989 reviews)

Jump to

Quality Control

Batch: Purity: 99.98%

99.98

Related Targets	ERK Raf JNK MEK Ras KRas S6 Kinase MAP4K TAK1 Mixed Lineage Kinase
Other p38 MAPK Inhibitors	SB202190 PH-797804 Doramapimod (BIRB 796) Ralimetinib (LY2228820) dimesylate VX-702 Losmapimod SB239063 Neflamapimod (VX-745) BMS-582949 Skepinone-L

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
PC12	Kinase Assay	10 μM	15 min		Inhibits p38 MAP kinase with IC50 of 0.6 μM	7750577
THP-1	Function Assay				Inhibits LPS-induced TNFalpha production with IC50 of 0.16 μM	18325768
PBMC	Function Assay		15 min	DMSO	Inhibits the release of interleukin-1-beta with IC50 of 0.037 μM	12361396
SW1353	Function Assay		1 h	DMSO	Inhibits IL-6 production with IC50 of 0.05 μM	11140741
Hela	Function Assay			DMSO	Inhibits Tat-induced HIV1 LTR transactivation in human HeLa cells with IC50 of 0.1 μM	18926711
PC12	Function Assay	10 μM		DMSO	Activates Nrf2/ARE in rat PC12 cells assessed as HO-1 protein induction	21345685
RAW 264.7	Cytotoxic Assay	12.5 μM	12h	DMSO	Blocks lethal toxin-mediated cytotoxicity	17485504
HCA2	Function Assay	2.5 μM			Inhibits p38 mediated MK2 activation	17964780
U937	Function Assay				Inhibits JAK-mediated interferon-gamma/anisomycin-induced Stat1 phosphorylation	18157122
U937	Function Assay				Inhibits JAK-mediated interferon-gamma/anisomycin-induced p38 phosphorylation	18157122
hESCs	Growth Inhibition Assay	5 μM		DMSO	Induces cardiomyogenic activity assessed as cell growth	23602399
RAW264.7	Function Assay	10 μM			Induces antiinflammatory activity by inhibiting IL-1β release	23791078
RAW264.7	Function Assay	10 μM			Induces antiinflammatory activity by inhibiting iNOS release	23791078
RAW264.7	Function Assay	10 μM			Induces antiinflammatory activity by inhibiting NO release	23791078
RAW264.7	Function Assay	10 μM			Inhibits LPS-induced p38 MAPK phosphorylation	24016057
IEC-18	Function Assay	10 μM			Inhibits LPS-induced p38 MAPK phosphorylation	23758110
Sf9	Function assay		30 mins		Inhibition of full-length FLAG-6His-TEV tagged human RIP2 expressed in Sf9 cells assessed as reduction in autophosphorylation pre-incubated for 30 mins followed by incubation with ATP for 2 hrs by ADP-Glo assay, IC50 = 0.01 μM.	26455654
sf21	Function assay				Binding affinity to wild type human biotin labelled p38 alpha (9 to 352 residues) expressed in sf21 insect cells SPR analysis, Kd = 0.0217 μM.	28834431
PBMC	Function assay				Inhibition of TNF-alpha production by lipopolysaccharide-stimulated human peripheral blood mononuclear cells, IC50 = 0.025 μM.	9873730
PBMC	Function assay				Inhibition of LPS-stimulated TH+NF-alphs production by human peripheral blood mononuclear cells (PBMCs), IC50 = 0.025 μM.	9784093
PBMC	Function assay				Inhibition of p38 MAP kinase related TNF-alpha release from peripheral blood mononuclear cells (PBMC), IC50 = 0.037 μM.	12061876
PBMC	Function assay				Inhibition of LPS-induced IL1-beta production in human peripheral blood mononuclear cells(PBMCs), IC50 = 0.048 μM.	9784093
SW1353	Function assay				Compound was evaluated for its ability to inhibit IL-6 production in SW1353 cells treated with cytokines IL-1 and TNF, IC50 = 0.05 μM.	10999467
SW1353	Function assay				Inhibition of TNF and IL-1 induced IL-6 production in human chondro-sarcoma SW 1353 cells, IC50 = 0.05 μM.	10999468
THP1	Function assay				Inhibition of LPS-stimulated IL1 production in human THP1 cells, IC50 = 0.05 μM.	18077363
THP1	Function assay				Inhibition of LPS-stimulated TNFalpha production in human THP1 cells, IC50 = 0.05 μM.	18077363
THP1	Function assay				Inhibition of LPS-induced tumor necrosis factor-alpha (TNF-alpha) production in THP-1 cells, EC50 = 0.06 μM.	12086485
THP1	Function assay				Inhibition of tumor necrosis factor alpha release by THP-1 cells, IC50 = 0.07 μM.	15658855
monocytic cell	Function assay				Inhibitory activity against TNF-alpha production using lipopolysaccharide stimulated human monocytic cells, IC50 = 0.072 μM.	12729637
THP1	Function assay				Inhibitory activity against LPS-stimulated TNF-alpha production in human monocytic cells (THP-1), IC50 = 0.072 μM.	15139749
THP-1	Function assay				Inhibitory activity against lipopolysaccharide stimulated TNF-alpha production in THP-1 cells (human monocytic cells), IC50 = 0.072 μM.	15837310
THP1	Function assay				Inhibition of LPS-stimulated TNFalpha production in THP1 cells, IC50 = 0.072 μM.	16750367
PBMC	Function assay				Inhibition of staphylococcal enterotoxin B(SEB) stimulated tumor necrosis factor alpha (TNF-alpha) production by human peripheral blood mononuclear cells(PBMCs), IC50 = 0.16 μM.	9784093
PBMC	Function assay				Concentration required to inhibit lipopolysaccharide induced TNF-alpha release was determined in human peripheral blood mononuclear cells, IC50 = 0.19 μM.	15454231
Sf9	Function assay				Inhibition of full-length FLAG-6His-TEV tagged human RIP2 expressed in Sf9 cells by fluorescent polarization assay, IC50 = 0.2 μM.	26455654
HEK293F	Function assay				Inhibition of sodium arsenate activated N-terminal GST-tagged Brugia malayi MPK1 expressed in HEK293F cells using FAM-p38tide as substrate by IMAP assay, IC50 = 0.22 μM.	29541362
HEK-293	Function assay				Inhibition of RIP2K in MDP-stimulated HEK-293 cells over-expressing NOD2 assessed as IL8 secretion, IC50 = 0.25 μM.	27109867
whole blood cell	Function assay	0.01 to 100 uM			Inhibition of p38-related IL1-beta release by whole blood cells at 10 e-4 to 10 e-8 M, IC50 = 0.35 μM.	12852754
PBMC	Function assay				Inhibition of p38 MAP kinase related TNF-alpha release from peripheral blood mononuclear cells (PBMC), IC50 = 0.59 μM.	12061876
PBMC	Function assay				Inhibition of the release of tumor necrosis factor alpha from peripheral blood mononuclear cells, IC50 = 0.59 μM.	12361396
PBMC	Function assay				Inhibitory activity against TNF-alpha release in PBM cells, IC50 = 0.59 μM.	12852754
whole blood cell	Function assay	0.01 to 100 uM			Inhibition of p38-related TNF-alpha release by whole blood cells at 10 e-4 to 10 e-8 M, IC50 = 0.94 μM.	12852754
BMDC	Antiinflammatory assay		1 hr		Antiinflammatory activity in C57BL/6 mouse BMDC cells assessed as inhibition of LPS-induced IL-6 production preincubated for 1 hr prior to LPS-stimulation measured after 18 hrs by ELISA, IC50 = 3.5 μM.	24047259
BMDC	Antiinflammatory assay		1 hr		Antiinflammatory activity in C57BL/6 mouse BMDC cells assessed as inhibition of LPS-induced IL-12 p40 production preincubated for 1 hr prior to LPS-stimulation measured after 18 hrs by ELISA, IC50 = 5 μM.	24047259
HEK-293	Function assay				Inhibition of RIP2K in Pam2CSK4-stimulated HEK-293 cells over-expressing TLR2 assessed as IL8 secretion, IC50 = 6.31 μM.	27109867
BMDC	Antiinflammatory assay		1 hr		Antiinflammatory activity in C57BL/6 mouse BMDC cells assessed as inhibition of LPS-induced TNFalpha production preincubated for 1 hr prior to LPS-stimulation measured after 18 hrs by ELISA, IC50 = 7.5 μM.	24047259
macrophage-like cell	Antiinflammatory assay		30 mins		Antiinflammatory activity in human HL-60 derived macrophage-like cells assessed as inhibition of LPS-induced TNFalpha production treated 30 mins before LPS stimulation measured after 24 hrs by ELISA, IC50 = 8.6 μM.	23811089
WS	Function assay	2.5 uM			Inhibition of anisomycin-induced P38-alpha activation in human human TERT-immortalised WS cells assessed as HSP27 phosphorylation at 2.5 uM	17659871
WS	Function assay				Inhibition of MK2 mediated HSP27 phosphorylation in immortalised WS cells assessed as reduction in F-actin stress fibres	17964780
WS	Function assay				Inhibition of p38 mediated MK2 activation in WS cells	17964780
A673	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	29435139
Saos-2	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	29435139
BT-37	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	29435139
RD	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	29435139
BT-12	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	29435139
OHS-50	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
SJ-GBM2	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	29435139
SK-N-MC	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

DMSO : 38 mg/mL (100.68 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5% DMSO 1 40% PEG 300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (13.25mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	377.43	Formula	C₂₁H₁₆FN₃OS	Storage (From the date of receipt)	3 years -20°C(in the dark) powder
CAS No.	152121-47-6	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	RWJ 64809, PB 203580			Smiles	CS(=O)C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F

Mechanism of Action

Features	First reported p38 inhibitor.
Targets/IC₅₀/Ki	p38 MAPK (THP-1 cells) 0.3 μM-0.5 μM PKB (THP-1 cells) 3 μM-5 μM
In vitro	Adezmapimod (SB203580) inhibits the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC50 of 3–5 μm. It also inhibits IL-2-induced p70S6 kinase activation, although the concentration required is slightly higher with an IC50 above 10 μm. This compound inhibits the activity of PDK1 in a dose-dependent manner with an IC50 in the 3–10 μm range. It inhibits p38-MAPK stimulation of MAPKAPK2 with an IC50 of approximately 0.07 μM, whereas total SAPK/JNK activity is inhibited with an IC50 of 3–10 μM. At higher concentrations, it activates the ERK pathway, which subsequently enhances NF-κB transcriptional activity. It also induces autophagy in human hepatocellular carcinoma (HCC) cells.
Kinase Assay	Cellular receptor kinase phosphorylation assay
Kinase Assay	4 μg of sheep anti-PKBα is immobilized on 25 μL of protein G-Sepharose overnight (or 1.5 hours) and washed in Buffer A (50 mm Tris, pH 7.5, 1 mm EDTA, 1 mm EGTA, 0.5 mm Na₃VO₄, 0.1% β-mercaptoethanol, 1% Triton X-100, 50 mm sodium fluoride, 5 mm sodium pyrophosphate, 0.1 mm phenylmethylsulfonyl fluoride, 1 μg/mL pepstatin, leupeptin, and 1 μm microcystin). The immobilized anti-PKB is then incubated with 0.5 ml of lysate (from 5 × 10⁶ cells) for 1.5 hours and washed three times in 0.5 mL of Buffer A supplemented with 0.5 m NaCl, two times in 0.5 mL of Buffer B (50 mm Tris-HCl, pH 7.5, 0.03% (w/v) Brij-35, 0.1 mm EGTA, and 0.1% β-mercaptoethanol), and twice with 100 μl of assay dilution buffer; 5× assay dilution buffer is 100 mm MOPS, pH 7.2, 125 mm β-glycerophosphate, 25 mm EGTA, 5 mm sodium orthovanadate, 5 mm DTT. To the PKB enzyme immune complex is added 10 μL of assay dilution buffer, 40 μm protein kinase A inhibitor peptide, 100 μm PKB-specific substrate peptide, and 10 μCi of [γ-³²P]ATP, all made up in assay dilution buffer. The reaction is incubated for 20 minutes at room temperature with shaking, then samples are pulse spun, and 40 μL of reaction volume are removed into another tube to which is added 20 μL of 40% trichloroacetic acid to stop the reaction. This is mixed and incubated for 5 minutes at room temperature, and 40 μL is transferred onto P81 phosphocellulose paper and allowed to bind for 30 seconds. The P81 piece is washed three times in 0.75% phosphoric acid then in acetone at room temperature. γ-³²P incorporation is then measured by scintillation counting.
In vivo	Adezmapimod (SB203580) protects pig myocardium against ischemic injury in an in vivo model. It is also effective in preventing and treating the disease in MRL/lpr mice model of Systemic lupus erythematosus (SLE).
References	[1] https://pubmed.ncbi.nlm.nih.gov/10702313/ [2] https://pubmed.ncbi.nlm.nih.gov/10960075/ [3] https://pubmed.ncbi.nlm.nih.gov/22170404/ [4] https://pubmed.ncbi.nlm.nih.gov/10710135/ [5] https://pubmed.ncbi.nlm.nih.gov/21549858/

Applications

Methods	Biomarkers	PMID
Western blot	phospho-p38 / p38 p-ASK1 / ASK1 / P-JNK / p-MKK4 / p-ERK phospho-MK2(T334) / phospho-HSP27(S82) / phospho-Akt(T308) / phospho-Akt(S473)	25747578
Immunofluorescence	dsRNA / hnRNP A1	25747578
Growth inhibition assay	Cell viability	23001390